Message from the Chief Sustainability Officer
Our Management Challenge Improve Sustainability to Maintain Society’s Trust.
Under its corporate philosophy of “We contribute to the healthier lives of people around the world through the creation of pharmaceuticals,” the Mitsubishi Tanabe Pharma Group believes that its social duty is to create and provide innovative pharmaceuticals that patients need. In March 2020, we made a new start as a wholly owned subsidiary of Mitsubishi Chemical Holdings (MCHC). With greater inter MCHC Group collaboration, we will contribute more than ever to the realization of KAITEKI the vision of MCHC.
The Group has identified seven material issues for sustainable growth. When we identified them, we sorted out the relationship between the Management of Sustainability (MOS) Indices for KAITEKI and the Sustainable Development Goals (SDGs) set by MCHC, as well as the Code of Conduct established by the Group. Goal 3 of the SDGs, “Good Health and Well-Being,” is the business mission of the Group and we consider it our most important goal. In fiscal 2019, we began monitoring our efforts by using indices established for each material issue.
With regard to the material issue “(1) Pharmaceuticals and healthcare services with differentiated value,” we are developing services that help improve diagnostic and treatment efficiency by utilizing digital technology. For example, we predict the risk of development and prognosis of suspected cases by analyzing information such as past prescriptions, biomarkers, and the medical records of patients who have been diagnosed with a certain disease. If such early detection and treatment are possible, it will help relieve financial pressure due to medical costs, a common issue in developed countries.
Medicago Inc., a consolidated affiliated company, is pursuing vaccine development and clinical trials to counter COVID-19. In addition, Mitsubishi Tanabe Pharma is examining the effects of existing drugs on post-infection treatment and control of severity.
We will continue to deliver value to a wide range of stakeholders including patients, their families, healthcare professionals, and local communities through our unique pharmaceuticals and services, and contribute to extending the healthy life expectancy of people.
Regarding the material issue “(4) Ethics, fairness and sincerity in business practices,” the Group has created a global governance system so that each employee in each country in the global system has high ethical standards and conducts business with fairness and integrity. We have also collaborated with MCHC, which has about 700 worldwide affiliates, to strengthen governance and compliance in each country, and will continue to improve global governance.
We have always emphasized the sixth material issue of “Employee health, diversity and inclusion,” and have been focusing on health management and workstyle reform-related initiatives. We have been able to maintain our business activities without significant turmoil, even during the COVID-19 pandemic, and though there are some challenges that have arisen due to this situation, we will further accelerate the carrying out of systematic reviews.
Fiscal 2020 marks the final year of our current medium-term management plan and is a critical year for formulating a new medium-term plan. In terms of backcasting from our fiscal 2030 vision, we are considering how to set our goals for 2025, and including targets for material issues and their monitoring indices in the plan. We also plan to further raise awareness within the Company about sustainability. Through these initiatives, the Mitsubishi Tanabe Pharma Group will continue to fulfill its responsibility as a global drug discovery company with the aim of maintaining society’s trust.